What's in ALK-Abelló A/S's pipeline?

ALK-Abelló A/S has 48 drugs in our index: 3 marketed, 0 filed, 21 in Phase 3, 21 in Phase 2, 3 in Phase 1.

Which companies overlap with ALK-Abelló A/S's portfolio?

Top competitors by shared drug class: Medical University of Silesia, Bausch & Lomb Incorporated, HAL Allergy, Medical University of Lodz, Anergis.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/alk-abell-a-s.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-09 · How we verify

ALK-Abelló A/S — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ALK-Abelló A/S pipeline: 3 marketed, 0 filed, 21 Phase 3, 21 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 21 Phase 3 21 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Pangramin Plus D. pteronyssinus 100%	Pangramin Plus D. pteronyssinus 100%	marketed
Grazax	Grazax	marketed			Other
AIT Tablet	AIT Tablet	marketed	Allergen immunotherapy		Immunology / Allergy
ALK HDM AIT 6 DU	ALK HDM AIT 6 DU	phase 3	Allergen immunotherapy vaccine	House dust mite allergens (Der p 1, Der p 2, Der f 1, Der f 2)	Immunology / Allergy
HDM SLIT-tablet (12 SQ-HDM)	HDM SLIT-tablet (12 SQ-HDM)	phase 3	Sublingual immunotherapy (SLIT) tablet		Immunology / Allergy
ALK HDM AIT 12 DU	ALK HDM AIT 12 DU	phase 3	Allergen immunotherapy vaccine	House dust mite allergens (Der p 1, Der p 2, and other HDM proteins)	Immunology / Allergy
subcutaneous immunotherapy	subcutaneous immunotherapy	phase 3	Immunomodulator		Immunology
MK-8237 tablets	MK-8237 tablets	phase 3			Immunology
SCH 697243	SCH 697243	phase 3	TLR9 agonist	TLR9	Oncology
Grazax-R	Grazax-R	phase 3	Sublingual immunotherapy (SLIT)	Grass pollen allergen (timothy grass, Phleum pratense)	Immunology / Allergy
HDM SLIT-tablet	HDM SLIT-tablet	phase 3	Sublingual immunotherapy (SLIT) tablet		Immunology / Allergy
Placebo for SCH 697243	Placebo for SCH 697243	phase 3

Therapeutic area mix

Immunology / Allergy · 10
Immunology · 4
Oncology · 3
Ophthalmology / Allergy · 2
Other · 1
Immunology / Respiratory · 1
Immunology; Allergy/Anaphylaxis · 1
Allergy/Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Medical University of Silesia · 2 shared drug classes
Bausch & Lomb Incorporated · 2 shared drug classes
HAL Allergy · 2 shared drug classes
Medical University of Lodz · 2 shared drug classes
Anergis · 1 shared drug class
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · 1 shared drug class
Active Biotech AB · 1 shared drug class
Allergopharma GmbH & Co. KG · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ALK-Abelló A/S:

Cite this brief

Drug Landscape (2026). ALK-Abelló A/S — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/alk-abell-a-s. Accessed 2026-06-09.